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Background: The growth factor heregulin (HRG) potently stimulates epithelial cell survival and proliferation
through the binding of its cognate receptor ErbB3 (also known as HER3). ErbB3-dependent signal transmission relies
on the dimerization partner ErbB2, a receptor tyrosine kinase that is frequently overexpressed and/or amplified in
breast cancer cells. Substantial evidence suggests that deregulated ErbB3 expression also contributes to the
transformed phenotype of breast cancer cells.
Results: By genome-wide screening, we identify 43 microRNAs (miRNAs) that specifically impact HRG-induced
activation of the PI3K-Akt pathway. Bioinformatic analysis combined with experimental validation reveals a highly
connected molecular miRNA-gene interaction network particularly for the negative screen hits. For selected miRNAs,
namely miR-149, miR-148b, miR-326, and miR-520a-3p, we demonstrate the simultaneous downregulation of the
ErbB3 receptor and multiple downstream signaling molecules, explaining their efficient dampening of HRG
responses and ascribing to these miRNAs potential context-dependent tumor suppressive functions.
Conclusions: Given the contribution of HRG signaling and the PI3K-Akt pathway in particular to tumorigenesis, this
study not only provides mechanistic insight into the function of miRNAs but also has implications for future clinical
applications.
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ErbB receptors play a well-established role in various types
of cancer, including those of the breast. The ErbB recep-
tors comprise four members: epidermal growth factor
receptor EGFR/ErbB1, ErbB2/HER2, ErbB3/HER3 and
ErbB4/HER4. In breast cancer, ErbB2/HER2 is found to be
amplified and/or overexpressed in up to 30% of patients,
correlating with poor prognosis [1,2]. Although ErbB2/
HER2 function can successfully be blocked with antibodies
such as Herceptin/Trastuzumab, a subset of tumors is
found to be non-responsive or tumor cells acquire resist-
ance during therapy. In this context, ErbB3/HER3 has
attracted growing attention because upregulation of signal-
ing through this receptor plays an important role in the re-
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unless otherwise stated.very efficient coupling of ErbB3 to the phosphatidylinositol
3-kinase (PI3K)/Akt survival pathway [1,2].
Signaling pathways activated by ErbB receptors include
the mitogen activated protein kinase (MAPK) and PI3K
pathways, which stimulate cellular responses such as
survival, proliferation, and migration. Ligand binding to
ErbB receptors induces the formation of homo- and het-
erodimers and activation of the intrinsic kinase domain,
resulting in the phosphorylation of a set of tyrosine resi-
dues within their cytoplasmic tails. These phosphory-
lated residues serve as docking sites for Src homology 2
and phosphotyrosine-binding domain containing pro-
teins, the recruitment of which leads to the activation of
specific intracellular signaling pathways [3,4]. The path-
ways activated are dependent upon the individual ErbB
receptors due to their ability to bind distinct effector
proteins. Heregulin (HRG) specifically binds to ErbB3
and ErbB4, inducing heterodimerization mainly with
ErbB2. Although ErbB2 has no direct ligand, it readily
dimerizes with the other ErbB receptors due to itsl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tural analyses [5]. ErbB3 is unique in that it has an im-
paired kinase domain lacking catalytic function, but in a
heterodimer with a signaling competent ErbB family
member, ErbB3 is transphosphorylated, thus serving as a
signaling platform. The presence of six binding sites for
p85, the regulatory subunit of PI3K, within the ErbB3
cytoplasmic tail explains the strong activation of this
pathway by ErbB3-containing heterodimeric ErbB receptor
complexes [6]. The production of PIP3 by PI3K recruits
Akt to the plasma membrane via its pleckstrin homology
domain, where Akt is then activated by phosphorylation
on threonine 308 by phosphoinositide-dependent kinase 1
and on serine 473 by mTOR complex 2 or DNA-PK, the
latter phosphorylation known to be required for full kinase
activity [7].
microRNAs (miRNAs) are 17-nt to 24-nt long non-
coding RNAs that regulate gene expression in metazoans
[8]. miRNAs act by partial complementary binding to
their target mRNAs usually within the 3′-untranslated
region (3′UTR), resulting in translational repression
and/or mRNA degradation [9]. Microarray and prote-
omic experiments have demonstrated the impact of a
single miRNA on fine-tuning expression of a hundred of
targets [10]. Fundamental biological cellular processes
such as development, proliferation, tumorigenesis and
apoptosis are now known to be regulated by miRNAs.
Furthermore, miRNAs are implicated in various diseases
including the development of cancer, making them attract-
ive targets for therapeutic intervention or as diagnostic
markers [11,12]. In recent years, miRNA profiling studies
undertaken in different tumor types have identified sets of
miRNAs that have altered expression in tumor versus nor-
mal tissue. While certain upregulated miRNAs, so-called
oncoMirs, such as miR-155 and the miR17-92 cluster have
been characterized to possess transforming potential, there
are also examples of miRNAs with inherent tumor sup-
pressive activity, such as the let-7 family, that are down-
regulated in cancer cells [11,12].
miRNAs that impact ErbB signaling are of special
interest due to the major contribution of this pathway to
cancer progression. miR-7 was one of first miRNAs
identified to simultaneously target EGFR and down-
stream signaling molecules including Raf1 [13,14]. Fur-
thermore, miR-125a and miR-125b* were shown to co-
target ErbB2 and ErbB3, which was accompanied by the
suppression of MAPK and PI3K signaling pathways [15].
miR-199a, on the other hand, contributes to enhanced
HRG-induced ErbB2-ErbB3 signaling. This miRNA ex-
erts its oncogenic effect by reducing the protein level of
Necl-2, which is involved in receptor dephosphorylation
via PTPN13 [16,17]. Moreover, upregulation of miR-21,
which targets the tumor suppressor and lipid phosphat-
ase PTEN and therefore promotes sustained ErbBreceptor signaling, was detected in cells with acquired
Herceptin resistance [18]. These examples of miRNA-
mediated regulation of the ErbB signaling network at
different levels illustrate the importance of miRNA regu-
lation and emphasizes their potential for prognostic and
therapeutic purposes.
Here, we performed a genome-wide miRNA screen in
the breast cancer cell line MCF7 based on Akt phos-
phorylation as a read-out to investigate the extent by
which miRNAs modulate the ErbB receptor signaling
pathway. Our data analysis identifies 43 miRNAs that
specifically regulate HRG-induced Akt activation, either
positively or negatively, and reveals the complexity of
coordinated miRNA-target interactions within the ErbB
signaling pathway. We further validate four miRNAs
with potential tumor suppressive function as novel regu-
lators of ErbB3 transcript and protein levels, the expres-
sion of which is shown to block HRG-dependent
proliferation. Our findings thus give mechanistic insight
into miRNA function and have implications for future
clinical applications.
Results
Screen establishment: analysis of heregulin-induced
signaling by miR-149
To screen for miRNA regulators of the ErbB receptor
pathway we chose MCF7 cells, a well characterized lu-
minal breast cancer cell line that expresses all four ErbB
receptors and is responsive to HRG. To establish the
screen and define the magnitude of miRNA-mediated ef-
fects, we first sought a control miRNA that directly targets
ErbB receptors. Because miR-125a, previously reported to
co-target ErbB2 and ErbB3 [15], did not affect expression
of these receptors in MCF7 cells (data not shown), we val-
idated miR-149 as a potential miRNA control. In a previ-
ous study, this tumor-suppressive miRNA was predicted
to affect the ErbB pathway based on KEGG pathway ana-
lysis [19]. Using the miRanda prediction algorithm (www.
microrna.org) we identified a conserved binding site for
hsa-miR-149-5p (miR-149) within the 3′-UTR of the
ErbB3 sequence (Figure 1A). Using a vector containing
the 3′UTR of ErbB3 cloned downstream of the luciferase
cDNA [15], we confirmed that miR-149 directly targets
ErbB3. Coexpression of a miR-149 mimic reduced lucifer-
ase activity in cell lysates compared to the activity mea-
sured in lysates from cells co-expressing the control
miRNA (Figure 1A). Deletion of the seven nucleotides
complementary to the miR-149 seed region from the po-
tential recognition motif in the ErbB3 3′UTR partially re-
stored luciferase activity, indicating that miR-149 blocks
luciferase expression by directly binding the ErbB3 3′UTR
(Figure 1A). Transient transfection of MCF7 cells with
miR-149 followed by qRT-PCR analysis and immunoblot-
ting revealed potent suppression of ErbB3 transcript and
Figure 1 miR-149 suppresses heregulin signaling. (A) miR-149 recognition site in the ErbB3 3′UTR (upper panel). HEK293T cells were co-
transfected with miR-con or miR-149 along with a luciferase reporter containing the wild-type (WT) or mutated ErbB3-UTR lacking the miR-149
seed region (mt; Δ527-533). The next day, cells were lysed and luciferase activity measured and normalized to the activity of the co-expressed
Renilla reporter (lower panel). Data correspond to the mean ± SEM of four independent experiments performed with triplicate samples. Data were
analyzed by one way Anova followed by Tukey’s multiple comparison test (**p < 0.01). (B) MCF7 cells were transfected with an ErbB3-specific
siRNA pool (siErbB3), miR-con or miR-149, respectively. Three days post transfection, RNA was extracted and ErbB3 levels were determined by
qRT-PCR. Values were normalized to GAPDH. Data are shown as the mean ± SEM of three independent experiments and analyzed by one-way
Anova followed by Tukey’s multiple comparison test (**p < 0.01). (C, D) MCF7 cells were transfected with miRNAs and siRNAs as indicated and
analyzed three days later. (C) Cells were lysed and ErbB3 expression analyzed by immunoblotting. Tubulin was detected as a loading control.
(D) Cells were left unstimulated (0 min) or stimulated with 10 ng/ml HRG for the indicated times prior to lysis. Cell lysates were analyzed by
immunoblotting using the indicated antibodies (E-G) Western Blot signals from two independent experiments were quantified by ImageJ. pAkt
signals were normalized to total Akt (E), whereas phosphorylated Erk signals were normalized to tubulin because total Erk levels were strongly
affected by miRNA expression (see G; signals at 0 min HRG). The unstimulated control was set to 1. The mean intensities ± SEM are shown.
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miRNA-control transfected cells (Figure 1B,C). As a posi-
tive control, an ErbB3-specific siRNA pool was used,
which efficiently silenced ErbB3 expression (Figure 1B,C).
Having established ErbB3 as a target of miR-149, we
next investigated the impact of miR-149 on HRG-induced
phosphorylation kinetics by immunoblotting of the recep-
tors and the downstream kinases Erk1/2 and Akt as
readouts for PI3K and MAPK pathways, respectively. In
agreement with the data shown in Figure 1C, miR-149 ex-
pression decreased ErbB3 protein levels, thereby impairing
HRG-induced phosphorylation and activation of ErbB3itself and its dimerization partner ErbB2 (Figure 1D). This
potent suppression of ErbB2/3 phosphorylation was ac-
companied by reduced Erk1/2 phosphorylation and mod-
estly reduced Akt(S473) phosphorylation (Figure 1D-F). In
the case of Akt(T308) phosphorylation, the levels in HRG-
stimulated control and miR-149 expressing cells were
similar, however, in the latter cells the fold induction was
reduced due to increased basal Akt(T308) phosphoryl-
ation (Figure 1D,E), possibly resulting from the compensa-
tory activation of feedback mechanisms. Apart from its
effect on ErbB3, miR-149 expression also reduced Erk1
protein levels, whereas only subtle changes in Erk2, Akt
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often co-regulate several targets within a specific signaling
pathway, it is possible that miR-149 also regulates Erk1
post-transcriptionally; alternatively, miR-149 may affect
Erk1 expression indirectly.
For screening purposes, we transferred the analysis of
HRG signaling to a 96-well format using an In-Cell
Western protocol (Figure 2A). This method is based on
the direct antibody staining of cells, and when combined
with IRDye-labeled secondary antibodies and the Odyssey
scanning system, it yields quantitative data and enables
the simultaneous detection of two signals in a single well.
Testing of the different phosphospecific antibodies used in
Figure 1D by In-Cell Western revealed that the pAkt
(T308)- and pErk-specific antibodies gave rise to spe-
cific and sustained signals upon HRG stimulation with
kinetics corresponding to those of the Western blot
(Additional file 1: Figure S1), whereas the pAkt(S473)-Figure 2 Genome-wide miRNA screen. (A) Workflow of the screening pro
human mimic miRNA library comprising 879 human miRNAs. Three days post
heregulin (HRG) for one hour followed by the detection of total Akt and phos
transfected with the indicated miRNAs and siRNAs and subjected to In-Cell W
was calculated as described in the Methods section. One representative exper
by one way Anova followed by Tukey’s multiple comparison test (**p < 0.01, *
For each replicate, the ratio of pAkt/Akt signal intensity and the difference betw
significantly (p < 0.05) altered Akt activity and had values of ΔpAkt < 1 o
(D) Correlation of the ratios of phosphorylated Akt and total Akt signal i
condition. (E) Screen data visualization: Akt activation upon HRG stimula
replicates for each miRNA is presented in ascending order.specific antibody did not yield a specific signal under
these conditions (data not shown). Considering the
greater dynamic range of the pAkt(T308) signal upon
stimulation of cells with different HRG concentrations
(Additional file 1: Figure S1), we selected the pAkt
(T308) antibody, an intermediate HRG concentration
(10 ng/ml) and stimulation of cells for 1 hour for our
high-throughput screen. Next, MCF7 cells were trans-
fected with a control miRNA, miR-149, a control siRNA
(siLacZ) and siRNAs against all members of the ErbB
family, stimulated with HRG followed by co-staining
with pAkt and Akt antibodies, respectively. In parallel,
unstimulated cells were stained to determine basal Akt
activity. pAkt/Akt ratios were determined for each sam-
ple and the basal values were then subtracted from the
HRG-stimulated ones, yielding ΔpAkt (see Methods for
details). Compared with the controls, ErbB2 and ErbB3
knockdowns almost completely abolished HRG-inducedcedure. MCF7 cells were transiently transfected in a 96-well format with a
transfection, cells were either left untreated (basal) or stimulated with
phorylated Akt(pT308) levels by In-Cell Western. (B) MCF7 cells were
estern as described in (A). Akt activation after HRG stimulation (ΔpAkt)
iment performed with triplicate samples is shown. The data was analyzed
**p < 0.001). (C) Workflow of the bioinformatic analysis of the screen data.
een untreated and stimulated samples were calculated. miRNAs that
r ΔpAkt > 2 for both replicates were considered as screen hits.
ntensities (pAkt/Akt) for the basal (left) and HRG-stimulated (right)
tion (ΔpAkt) for each miRNA is plotted. The mean of the two
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fects (Figure 2B), confirming that ErbB2/3 is the relevant
signal heterodimer in this setting. Compared to the
miRNA control, ectopic expression of miR-149 reduced
ΔpAkt by ~40% (Figure 2B), in accordance with the re-
duced fold induction observed byWestern blot (Figure 1E),
demonstrating that miRNA-mediated modulation of ErbB
receptor signaling can be quantified using this method.
Genome-wide miRNA screening for regulators of
HRG-induced Akt activation
In-Cell Western screening of a miRNA mimic library
comprising 879 miRNAs (Additional file 2: Table S1)
was performed as detailed in Figure 2A. The screen was
repeated to obtain a second independent data set for both
the basal and HRG-stimulated condition. Screen data were
then normalized by determining pAkt/Akt ratios for all
replicate samples (see Additional file 2: Table S2 for raw
data). For quality control, the replicates were correlated
yielding an average Pearson’s coefficient of 0.74 (basal)
and 0.68 (HRG), respectively (Figure 2D). HRG-induced
Akt activation was determined and plotted for all miRNAs
(ΔpAkt; Figure 2C). The majority of miRNAs had no
effect on ΔpAkt values and clustered in the range of the
negative controls miR-con and siLacZ (Figure 2E;
Additional file 1: Figure S2). By contrast, ΔpAkt values
for the positive controls miR-149, siErbB2 and siErbB3
were ≤1 (Figure 2E, Additional file 1: Figure S2) and
therefore used to define a cut-off: Only those miRNAs
were considered as screen hits for which ΔpAkt changes
were significant and either below 1 or greater than 2
(Figure 2C,E). 43 miRNAs met these criteria, 19 of
which significantly reduced (ΔpAkt < 1) and 24 of which
significantly increased HRG-induced Akt activation
(ΔpAkt > 2).
In Figure 3, the ΔpAkt values as well as the basal and
HRG-stimulated pAkt/Akt ratios are depicted for the
miRNA screen hits. Red coloring indicates an increase,
green coloring a decrease of the pAkt/Akt level com-
pared to that in miR-con expressing cells. This reveals
that those miRNAs that enhance HRG-stimulated pAkt/
Akt levels generally suppress basal pAkt/Akt levels. This
is most pronounced for miR-886-3p, for which the
greatest difference in HRG-induced Akt activation is
observed (ΔpAkt = 3.25). In the case of miR-1304 and
miR-654-3p, basal pAkt/Akt levels were unaffected, thus,
the increase in ΔpAkt was specifically due to enhanced
Akt activity upon HRG stimulation. For those miRNAs
that negatively affected ΔpAkt, there was no uniform
trend regarding basal pAkt/Akt levels, as some miRNAs
such as miR-204 enhanced, whereas others, e.g. miR-
520a-3p, reduced basal pAkt/Akt levels. Regardless of
the effect on basal Akt activity, all miRNA hits in this
category attenuated Akt activation in response to HRG.This is best reflected by miR-148b, for which the lowest
ΔpAkt value was obtained, indicating almost complete
suppression of HRG-induced Akt activation. Furthermore,
a general reduction of pAkt/Akt levels for the basal and
HRG-stimulated situation is seen for miR-520a-3p, miR-
519c-3p, miR-485-3p, miR-302c and miR-520d-3p. Not-
ably, three of these miRNAs possess the same seed region,
which is critical for target recognition. The similar ΔpAkt
values obtained for the different seed family members
underscores the reliability of the screen and suggests that
the effects of these miRNAs are mediated by common
targets (Figure 3B).
Construction of an ErbB/Akt signaling network with
integrated miRNA-target information
For network construction we used data from the Reac-
tome database [20] and identified 24 pathways con-
nected to ErbB/Akt signaling. These pathways were
parsed into R using r-package rBiopaxParser [21] as di-
rected graphs. Next, 24 graphs were merged into a single
signaling network, comprising 312 nodes representing
genes, and 3582 edges representing activation or inhib-
ition effects. Because some of the genes are components
of protein complexes, to simplify the network, we
merged these gene-nodes into protein-complex-nodes.
This was done for PIK3 (PIK3CA, PIK3R1), mTORC1
(AKT1S1, MLST8, MTOR) and mTORC2 (RICTOR,
MLST8, MTOR), finally yielding 309 nodes and 3542
edges. To acquire miRNA-target information for the 43
screen hit miRNAs, we searched 3 databases with com-
putationally predicted miRNA targets: MicroCosm Tar-
gets release v5 [22], miRDB v4.0 [23] and microRNA.org
August 2010 release [24]. For 3 miRNAs (miR-1304, miR-
1259, miR-1915) no targets were found in these databases.
The remaining 40 miRNAs were divided into two groups:
a first group with negative effects on ΔpAkt (19 miRNAs),
and a second group with positive effects on ΔpAkt (21
miRNAs). We pooled miRNA – target information from
all three databases and identified 298 target genes in the
ErbB/Akt signaling network (see Additional file 2: Table S3).
Next, we separately connected both groups of miRNAs
with the network by 959 and 750 miRNA – target gene
edges for the first and second miRNA group, respectively.
This resulted in the construction of two miRNA-ErbB/
Akt signaling networks. To visualize these networks, the
target genes in each network were ranked by the number
of targeting miRNAs and the top target genes were then
selected. For the network with miRNAs that negatively af-
fected ΔpAkt, a sub-network comprising the top 14 genes
targeted by 9 or more miRNAs was extracted with corre-
sponding miRNAs. In the case of the network with posi-
tively acting miRNAs, a sub-network of top 17 genes,
targeted by 6 or more miRNAs, was extracted with corre-
sponding miRNAs (Additional file 1: Figures S4 and S5).
Figure 3 Analysis of the screen data. (A) Screen hits depicted in list format. Mean values of the pAkt/Akt ratios for the basal and HRG-stimulated
condition are shown, with green indicating a reduction and red an increase compared to the mean of miR-con (black). ΔpAkt values (mean of the two
replicates) for each miRNA screen hit is shown as a bar chart. (B)miRNAs were clustered according to their seed region and for each miRNA ΔpAkt is
visualized as a color-coded value. All seed families with more than 3 members are listed. Values correspond to the mean of the two replicates.
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target genes identified for negatively and positively acting
mRNAs differed, showing little overlap.
Next, we focused our attention on those miRNAs that
reduced Akt activation because their effect can be ex-
plained by the direct targeting of key players within the
ErbB-Akt pathway. Interestingly, ErbB3 and PIK3 were
among the most frequently predicted target genes. To
investigate in more detail the potential co-regulation of
these genes, we created a miRNA-protein interaction
graph that integrated additional information on protein-
protein interactions from the STRING database [25] and
comprised only directly connected proteins and miRNAs
predicted to target ErbB3, namely miR-520a-3p, miR-520d-3p, miR-302c, miR-19a, miR-148b, miR-204, miR-
155, miR-149, miR-326 (Figure 4 and Additional file 1:
Figure S3). Intriguingly, all nine miRNAs, of which only
520a-3p, 520d-3p and 302c were members of the same
seed family, had largely overlapping target spectra. Apart
from ErbB3 and PIK3, genes such as RAP1A, a member
of the Ras GTPase family, mTOR complex 2, the Ras
GDP exchange factor SOS1 and the metalloproteinase
Adam17/Tace were predicted as targets. This indicates
that this subset of miRNAs negatively regulates HRG-
induced Akt activation by targeting the PI3K pathway at
multiple levels, thereby multiplying the effects caused by
the post-transcriptional suppression of single pathway
components.
Figure 4 miRNA-protein interaction network for negative regulators of HRG signaling. The 14 most frequently targeted genes plus Akt are
shown. The edges are based on signaling data of Reactome and protein-protein interactions of STRING databases. Only those miRNAs that
co-target ErbB3 are depicted.
Bischoff et al. Cell Communication and Signaling  (2015) 13:5 Page 7 of 15miR-148b, miR-149, miR-326 and miR-520a reduce ErbB3
expression and dampen HRG-induced MAPK and PI3K
signaling
We next sought to validate ErbB3 as a target for select
miRNA screen hits: miR-148b gave rise to the strongest
reduction of ΔpAkt; miR-520a-3p was chosen as a repre-
sentative of the 520/302 seed family; miR-326 was the
only miRNA for which no co-regulation of ErbB3 and
PIK3 was predicted. To this end, MCF7 cells were tran-
siently transfected with the non-targeting control
miRNA (miR-con), miR-148b, miR-326 and miR-520a-
3p, followed by Western blot analyses of total cell ly-
sates. In line with the target prediction, reduced ErbB3
expression was confirmed for miR-148b, miR-326, and
miR-520a-3p (Figure 5A). By contrast, downregulation
of the catalytic subunit of PIK3 (PI3K p110α) was only
evident in cells overexpressing miR-520a-3p (Figure 5A).
qRT-PCR analyses further confirmed reduced ErbB3
transcript levels (Figure 5B), suggesting that the ErbB3
mRNA is targeted by miR-148b, miR-326, and miR-520a-3p. To test this directly, luciferase expression
vectors with mRNA regions of ErbB3 containing the
predicted binding sites of these miRNAs were generated
as detailed in the Methods section. Co-transfection of
miR-148b, miR-326 or miR-520a-3p with the different
luciferase expression vectors suppressed luciferase activ-
ities, which was fully restored by deletion of the respective
seed regions from the predicted binding sites (Figure 5C,
Additional file 1: Figure S7), providing evidence for the
direct targeting of the ErbB3 mRNA by miR-148b, miR-
326 and miR-520a-3p.
To explore the extent by which these miRNAs trig-
gered degradation of additional targets associated with
the ErbB signaling network, we further assessed SOS1,
Adam17, and Rap1a mRNA levels by qRT-PCR. These
experiments revealed miRNA-induced downregulation
of Adam17 and SOS1 transcripts in all cases (Figure 5D),
in accordance with the target prediction. However,
Rap1a transcript levels were only suppressed by miR-
149 (Figure 5D). It is possible that miR-148b and miR-
Figure 5 miR-148b, miR-326 and miR-520a affect the ErbB signaling pathway at multiple levels. (A) MCF7 cells were transfected with
miR-con, miR-148b, miR-326 and miR-520a (miR-520a-3p), respectively. Three days after transfection, cells were lysed and lysates analyzed by
immunoblotting using ErbB3 and PI3K p110α specific antibodies. Tubulin was detected to confirm equal loading. A representative Western blot is
shown; the left panels are from the same blot. Signals were quantified by ImageJ and normalized to those of tubulin. Data are shown as the mean ±
SEM of three to five independent experiments and analyzed by one way Anova followed by Tukey’s multiple comparison test (* p < 0.05). (B) MCF7
cells were transfected with the indicated miRNAs. Two days post transfection, RNA was extracted and ErbB3 levels were determined by qRT-PCR. Values
were normalized to GAPDH. Data are shown as the mean ± SEM of two independent experiments. (C) HEK293T cells were co-transfected with the
indicated miRNAs and the different luciferase reporter constructs containing wild-type (WT) ErbB3 mRNA sequences or those lacking the respective
miRNA seed regions (mt) (see Methods and Additional file 1: Figure S7). The next day, cells were lysed and luciferase activity measured and normalized
to the activity of the co-expressed Renilla reporter. Data correspond to the mean ± SEM of three independent experiments performed with at least
triplicate samples. Data analysis: one way Anova followed by Tukey’s multiple comparison test (*p < 0.05, ***p < 0.001). (D) MCF7 cells were transfected
with the indicated miRNAs. Three days post transfection, RNA was extracted and SOS1, ADAM17 and RAP1A levels were determined by qRT-PCR. Values
were normalized to GAPDH. Data are shown as the mean ± SEM of three independent experiments and analyzed by one way Anova followed by
Tukey’s multiple comparison test (*p < 0.05).
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inhibition rather than degradation, however, it should
also be noted that in silico prediction algorithms give
rise to false positives and therefore any candidates must
be experimentally validated as genuine targets. Never-
theless, our analysis confirms the simultaneous suppres-
sion of a number of ErbB pathway molecules by the
miRNA screen hits at the transcript level.
miR-148b, miR-149, miR-326 and miR-520a reduce
HRG-induced signaling and viability. We next investi-
gated how the selected miRNAs affected ErbB2/3 receptor
activation and downstream signaling by immunoblotting
of cell lysates derived from HRG-stimulated cells. In
agreement with Figure 5A, the expression of miR-148b,
miR-326 and miR-520a-3p reduced ErbB3 protein andphosphorylation levels, which was accompanied by reduced
ErbB2, Akt and Erk1/2 phosphorylation (Figure 6A, C-D).
In addition, overexpression of miR-148b and miR-520a-3p
reduced Erk2 protein levels, whereas miR-326 affected
both, Erk1 and Erk2 (Figure 6A,B). Erk1/2 are not predicted
targets for these miRNAs based on perfect base pairing of
the seed region, however, increasing evidence suggests that
nucleotides other than the seed region contribute to effi-
cient miRNA targeting. Furthermore, ErbB2 and Erk1 levels
were increased by miR-520a-3p expression, possibly result-
ing from compensatory mechanisms. Taken together, these
experiments confirm that miR-148b, miR-326 and miR-
520a-3p reduce ErbB3 expression and severely impact
HRG-induced ErbB receptor downstream signaling. HRG
signaling was also negatively affected by miR-149 and miR-
Figure 6 miRNA inhibition of HRG-dependent signaling and cell viability. MCF7 cells were transfected with the indicated miRNAs. (A) Three
days after transfection, cells were either left untreated (0 min) or stimulated with 10 ng/ml HRG for the indicated times prior to lysis. Equal amounts of
cell lysate were analyzed by immunoblotting using antibodies specific for ErbB3(pY1289), ErbB2(pY1221/1222), Akt(pT308), Akt(pS473), and Erk1/2
(pT202/pY204). Membranes were further probed with antibodies that detect the total level of these proteins. Tubulin was detected to confirm equal
loading. (B-D) Western Blot signals from (A) as a representative experiment were quantified by ImageJ. pAkt signals were normalized to total Akt
(C), whereas phosphorylated Erk signals were normalized to tubulin (D) because total Erk levels were strongly affected by miRNA expression (see B;
signals at 0 min HRG). The unstimulated control was set to 1. (E) One day after transfection, cells were plated into 96-well plates and grown in medium
containing 0.5% FCS (− HRG) and 0.5% FCS supplemented with 5 ng/ml HRG (+ HRG), respectively. Five days later, cells were fixed and stained
with crystal violet and the absorbance at 550 nm was measured. Data were normalized to the basal growth in 0.5% FCS. The mean ± SEM of
2–4 independent experiments is shown.
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with ErbB2 amplification. In both cases, miRNA expression
suppressed ErbB3 expression and reduced HRG-induced
Akt and Erk phosphorylation (Additional file 1: Figure S8A),
however, in the case of miR-148b no suppression was ob-
served (data not shown). Note that miR-149 expression
appears to favor HRG-induced ErbB3 degradation in these
cells, demonstrating that the precise signaling response
differs in different cell lines. A recent study by the Sorger
lab on growth factor signaling in different cell lines
supports the view that growth factor responses across
different breast cancer cell lines are diverse, even within
the same subtype [26]. This diversity was found to arise
from the variation in the abundance of the receptors
themselves and in the abundance and activity of down-
stream signaling molecules.HRG is known to support the viability of breast cancer
cells. To assess the impact of the selected negative miRNA
screen hits in a biological assay, we measured the viability
of MCF7 cells ectopically expressing miR-148b, miR-149,
miR-326 and miR-520a-3p in the presence of HRG. In
control cells, viability was increased 2.8 fold in medium
containing 0.5% FCS and HRG compared with medium
supplemented with 0.5% FCS only (Figure 6E). In the pres-
ence of HRG, the viability of cells was reduced by all miR-
NAs (Figure 6E). Furthermore and consistent with the
inhibition of HRG signaling, miR-149 and miR-520a-3p
suppressed the migration of SKBR3 cells in Transwell as-
says containing HRG in the bottom chamber (Additional
file 1: Figure S8B). These data provide support for the
inhibition of HRG-induced biological responses by these
miRNAs and their potential tumor suppressive function.
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The tight control of HRG responses is of fundamental
importance for proper cell function as, on the one hand,
HRG-induced signaling is essential for the morphogen-
esis and differentiation of the mammary gland [27] and,
on the other hand, up-regulation of HRG signaling is
sufficient to drive malignant transformation and the de-
velopment of tumors in the breast [28]. Here, we identi-
fied by genome-wide screening miRNAs that modulate
HRG-induced Akt activation in MCF7 breast cancer
cells. By setting a stringent cut-off requiring effects to be
at least as potent as those of miR-149, we identified 43
miRNAs that specifically altered HRG-induced Akt acti-
vation, with 24 increasing and 19 decreasing Akt activa-
tion. The similar results obtained for individual miRNA
seed family members underscore the importance of this
region in target selection and prove the robustness of
our screen. In addition to miR-149, nine miRNA screen
hits that suppressed HRG-induced Akt activation were
predicted to target the ErbB signaling network at the
level of ErbB3 concomitant with key downstream ef-
fector proteins. Three miRNAs, namely miR-148b, miR-
326 and miR-520a-3p as a representative of the miR-520
seed family, were validated to reduce both ErbB3 tran-
script and protein levels, indicating that these miRNAs,
similarly to miR-149, target ErbB3 directly.
Despite its ligand-independent active conformation,
ErbB2-induced transformation of breast cancer cells is
dependent on ErbB3 [29,30]. Moreover, due to the po-
tent activation of the PI3K survival pathway, ErbB3 plays
an important role in the responsiveness of cancer cells
to targeted therapies. Breast cancer cells were shown to
upregulate ErbB3 via multiple mechanisms to escape
pharmacological EGFR inhibition [31], and in lung cancer
cells, autocrine activation of ErbB3 caused resistance to
the EGFR-specific small molecule inhibitor Gefitinib [32].
miRNA alterations may thus modulate the efficacy of such
treatments by impacting ErbB3 expression. In support of
this hypothesis, drug-resistant MCF7 cells showed down-
regulation of miR-326 and ectopic re-expression sensitized
cells to doxorobucin [33]. Additionally, in SKBR3 cells,
miR-205, previously shown to target ErbB3, blocked Akt
activity and increased the response to the pharmacological
ErbB inhibitors Gefitinib and Lapatinib [34].
Because miRNAs tend to have moderate effects on the
expression of a single gene, the simultaneous targeting of
several genes contained within a functional signaling unit
appears to be a common mechanism by which miRNA ef-
ficacy is increased. Such multifaceted targeting was also
observed by Uhlmann et al., investigating the EGFR-
driven cell cycle pathway in MDA-MB-231 breast cancer
cells [35]. Specifically, apart from controlling ErbB3 ex-
pression, the negatively acting miRNAs analyzed also tar-
geted Adam17 (Figures 4 and 5D). This metalloproteinaseplays an important role in the shedding of ErbB ligands,
leading to autocrine and paracrine stimulation of cancer
cells, a mechanism often activated in drug resistance [36].
It will be interesting to validate in future studies the sup-
pression of Adam17 at the protein level and investigate its
contribution to cell autonomous signaling in the context
of the screen hit miRNAs.
We further provide evidence that miR-149, miR-326,
miR-148b and miR-520a-3p block HRG-mediated viability
of MCF7 cells and thus possess tumor suppressive proper-
ties. In support of this, miR-148b was reported to be
downregulated in gastric cancers and aggressive breast tu-
mors where it was identified to target multiple genes in-
volved in cell signaling, including PIK3CA [37,38]. The
latter regulation, however, appears to depend on the cell
type, as miR-148b did not affect PIK3CA expression in
MCF7 cells, in accordance with our observations. Simi-
larly, a recent miRNA screen performed in the ErbB2
amplified cell lines KPL-4 and JIMT-1 identified several
miRNAs that directly targeted the human ErbB2 UTR
[39], none of which were identified by our screen. Consid-
ering that the ectopic expression of miR-125a previously
reported to target ErbB2 [15], did not affect ErbB2 levels
in MCF7 cells suggests that miRNA regulation of this re-
ceptor is also highly cell type specific. This may be associ-
ated with the fact that the ErbB2 3′UTR does not contain
sites that are well conserved amongst mammals [13].
Bioinformatic analysis of the screen data combined
with predicted miRNA targets and experimental valid-
ation further revealed connections between parallel
pathways. The downregulation of Erk1/2 and SOS1 by
miR-149, miR-326 and miR-520a-3p plus the predicted
targeting of signaling molecules such as FRS2 and Gab1
uncover extensive miRNA-dependent co-regulation of
the PI3K and MAPK pathways. Our screen analysis fur-
ther highlights the interdependence of growth factor and
integrin signaling. Rap1a is a small GTPase that is pivotal
for integrin activation [40]. Data from our lab shows that
miR-149 suppresses Rap1a/b in basal breast cancer cells
and impairs cell spreading, migration, and invasion in vitro,
and lung metastasis formation in vivo [19]. The coordinate
suppression of survival, proliferative and migratory path-
ways was also seen in the case of miR-148b [37]. Similarly,
the miR-520 family was shown to suppress both NFκB and
TGFβ signaling in breast cancer cells, providing another
example of pathway co-regulation by miRNAs [41].
Of the 24 miRNAs identified to enhance HRG-induced
Akt activation, some are likely to possess oncogenic func-
tion. The respective miRNA-gene network was less com-
plex and interconnected, reflecting the fact that fewer
negative regulators are contained within the ErbB signal-
ing pathway. Thus, apart from the screening data, the
reconstructed miRNA-gene networks are influenced by
the choice of databases used to link the miRNA targets to
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trieved from Reactome, a manually curated and fast grow-
ing pathway database, and combined with protein-protein
interaction data. For the identification of potential miRNA
targets of the screen hits we used three major databases of
computationally predicted miRNA targets using different
prediction algorithms to ensure finding as many potential
targets as possible. The distinct miRNA-gene networks
obtained for the positive and negative screen hits confirm
the validity of this approach. However, these networks
have to be seen within the limitation of the prior know-
ledge used for their construction. Nevertheless, target val-
idation for the positively acting miRNAs is also of interest
as they may regulate the expression of tumor suppressor
genes. Intriguingly, PTEN was not identified as a top
miRNA-regulated gene by our screen data analysis, al-
though this lipid phosphatase is one of the most important
negative regulators of the PI3K pathway. There are reports
on PTEN targeting by miRNAs, e.g. miR-21, miR-22, and
miR-221/2 [42], but protein loss by mutations, promoter
methylation, and LOH may be more common mecha-
nisms of PTEN inactivation. However, because PTEN
downregulation increases both basal and HRG-induced
Akt activity, miRNAs acting on PTEN may not have been
enriched by our analysis filtering those miRNAs that spe-
cifically increased Akt activation in response to HRG
stimulation. Instead, the phosphatases INPP4A/B and
INPP5B involved in phosphoinositide metabolism, and
PHLPP2, which directly desphosphorylates Akt, were
enriched in our miRNA target gene list, raising the possi-
bility that these phosphatases are potentially more prone
to regulation by miRNAs and are particularly involved in
determining the amplitude of the HRG response.
In many cases, the miRNAs identified by our screen dif-
ferentially affected phospho-Akt levels, depending on
whether cells were stimulated or not. In our experimental
set-up, cells were given three days to adapt to transfection,
during which transcriptional changes and feedback mech-
anisms are likely to impact basal Akt phosphorylation.
This differs from the acute stimulation with HRG, for
which the expression levels and activity states of the direct
upstream regulators of Akt are likely to dominate the re-
sponse. For example, miR-155 enhanced basal Akt activity,
while suppressing HRG-induced Akt activity. miR-155 is
an established oncomiR that is upregulated in various can-
cers including those of the breast. Inhibition of endogen-
ous miR-155 resulted in cell cycle arrest and the induction
of apoptosis, whereas ectopic expression promoted sur-
vival, proliferation and chemoresistance of breast cancer
cells [43]. These results are consistent with a role for miR-
155 as a positive regulator of basal PI3K pathway activa-
tion. By contrast, miRNAs whose expression reduced basal
Akt activity may be important for the control of cell
homeostasis and indeed there was a trend towardreduced cell numbers upon transfection of these miR-
NAs (Additional file 1: Figure S6). However, it should
be noted that the alteration of a single pathway is not
sufficient to classify a given miRNA as oncogenic or tumor
suppressive. For example, in MCF7 cells, members of
the miR-520/373 family, which potently suppressed
phospho-Akt levels associated with the inhibition of cell
proliferation, were reported to promote breast cancer
metastasis by targeting CD44 [44]. In ER negative breast
cancer cells, however, miR-520c inhibited in vitro cell
invasion and in vivo intravasation, and its expression in pa-
tient samples was inversely correlated to lymph node me-
tastasis [41]. Together, these observations highlight the fact
that miRNAs act in a context-dependent and stage-specific
manner.
Conclusions
Clinical trials have shown the limited efficacy of single-
agent Akt pathway inhibitors, presumably due to the ac-
tivation of compensatory signaling feedbacks [45]. Given
their promiscuous target selection, miRNAs may effi-
ciently block such cellular evasion strategies. Furthermore,
cancer cells often harbor activating mutations in key path-
way molecules, making them resistant to pharmacological
inhibition while sensitivity to miRNA regulation should
remain. By targeting the Akt pathway at multiple levels,
the miRNAs identified in this study may not only be
relevant to HRG signaling as Akt is activated downstream
of different cancer-promoting RTKs via conserved mecha-
nisms, implying broader clinical applications. Increasing
the molecular understanding of miRNA function together
with the development of improved delivery systems are
prerequisites for the translation of miRNAs to the clinic as
anti-cancer therapeutics. The identification and functional
characterization of miRNAs targeting the ErbB receptor
signaling network and the PI3K pathway in particular are
first steps in this direction.
Methods
Plasmid constructs
The pGL3-ErbB3 3′UTR firefly luciferase plasmid com-
prising the first ~700 nucleotides of the ErbB3 3′UTR
was kindly provided by Christopher C. Benz [15]. Within
the ErbB3 3′UTR, seed regions of miR-149 (527–533) and
miR-520a-3p (514–520 and 664–670), respectively, were
deleted by site-directed mutagenesis using the pGL3-
ErbB3 3′UTR firefly luciferase plasmid as a template






GGC-3′. The ErbB3 mRNA regions 4192–4383 and
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miR-148b and miR-326 binding sites, respectively, were
amplified by PCR using genomic DNA from MCF7 cells
as a template and the following primer pairs: ErbB3-
4192 forward 5′-TTTTTCTAGACATTATGCCCGCCT
AAAAACTCT-3′, ErbB3-4383 reverse 5′- TTTTCTA
GAGGGAATAGGGAGAAGACGGTA-3′ and ErbB3-
5286 forward 5′- TTTTCTAGATCCTCCCAATTCCT
GTGCAT-3′, ErbB3-5470 reverse 5′-TTTTCTAGAC
CTTCTGACTACCCCCACCA-3′. The PCR products
were cloned into the XbaI site of the pGL3 vector and,
in a second step, the miR-148b (5382–5388) and miR-
326 (4292–4298) binding sites were deleted by site-
directed mutagenesis using pGL3-ErbB3-4192-4383 and
pGL3-ErbB3-5286-5470 as templates and the respective
forward primers: ErbB3-del-4292 forward 5′- CCCCAA
GGCTAATGAACGTAACTCCTGC-3′, and ErbB3-del-
5382 forward 5′-GGCACTGTTTCTTGTTTTAATCA
AGTCTAACCCC-3′. Primers were synthesized by MWG,
Ebersberg, Germany. Successful cloning and mutagenesis
was verified by sequencing (GATC Biotech AG, Konstanz,
Germany). The pRL-TK Renilla Luciferase Control Re-
porter Plasmid was from Promega (Madison, WI, USA).
Antibodies and reagents
Antibodies used for immunoblotting were: rabbit anti-
pErbB2(Y1221/1222) mAb, rabbit anti-pErbB3(Y1289)
mAb, rabbit anti-pAkt(T308) mAb, rabbit anti-pAkt
(S473) mAb, rabbit anti-pERK1/2(T202/Y204) pAb,
mouse anti-ERK1/2 mAb, mouse anti-Akt(pan) mAb,
rabbit anti-PI3K p110α mAb (Cell Signaling, Danvers,
MA, USA), mouse anti-ErbB2 mAb, mouse anti-ErbB3
mAb (Thermo Scientific, Fremont, MA, USA), and mouse
anti-tubulin mAb (Sigma-Aldrich, St Louis, MO, USA).
HRP-labeled secondary anti-mouse and anti-rabbit IgG
antibodies were from GE Healthcare (Buckinghamshire,
UK) and IRDye-680LT anti-rabbit IgG or IRDye-800CW
anti-mouse IgG conjugated secondary antibodies were
from LI-COR Biosciences (Lincoln, NE, USA). Heregu-
linβ1 (HRG) was from Peprotech, Rocky Hill, NJ, USA.
Cell culture and transfection
MCF7 and HEK293T cells were cultured in RPMI 1640
(Life Technologies, Carlsbad, CA, USA), and SKBR3
cells in DMEM (Life Technologies), supplemented with
10% FCS (PAA Laboratories, Cölbe, Germany). Cells
were incubated in a humidified atmosphere of 5% CO2
at 37°C. Cells were transfected with siRNAs and miRNAs
in a final concentration of 10 nM using RNAiMax (Life
Technologies) according to manufacturer’s instructions.
miRNA-148b, miR-149-5p, miRNA-326, miR-520a-3p,
miRNA mimic negative control #1, EGFR-, ErbB3- and
ErbB4-SMARTpools were synthesized by Thermo Scien-
tific, Carlsbad, CA, USA. siLacZ (5′-GCGGCUGCCGGAAUUUACC-3’) and siErbB2 (5’-GGACGAAUUCUGC
ACAAUG-3’) were synthesized by MWG.Luciferase assays
4 × 104 HEK293T cells were plated into 96-well plates.
The next day, cells were cotransfected with 10 ng wild-
type or mutated ErbB3 pGL3 firefly luciferase plasmid,
10 ng pRL Renilla luciferase plasmid, and 50 nM miRNA
using Lipofectamine 2000 (Invitrogen). 24 h after trans-
fection, cells were lysed with passive lysis buffer (Pro-
mega). The activities of the luciferases were measured by
sequential substrate addition as described by Dyer et al.
[46] and detection at 562 nm with the multimode reader
Infinite® 200 PRO (Tecan). Firefly luciferase activities
were normalized to those of Renilla luciferase activities
in each sample.Quantitative PCR
Total RNA was isolated from 5 × 105-1 × 106 cells using
the mirVANA™ miRNA Isolation Kit (Life Technologies)
according to the manufacturer’s protocol. Primers for
ErbB3, RAP1A and GAPDH were QuantiTect Primer
Assays from Qiagen, primers for SOS1 (forward: 5’-C
GAGCCCTTTTCACTCAAGC; reverse: 5’-GCCATGGG
GCAGAGTAACTT). were designed using PRIMER3
[47,48] and synthesized by biomers.net GmbH, Ulm,
Germany. ErbB3, SOS1, RAP1A and GAPDH mRNA
levels were quantified by qRT-PCR using the QuantiTect
SYBR Green RT-PCR Kit (Qiagen, Foster City, CA, USA)
according to manufacturer’s protocol. qRT-PCR was per-
formed with a Cfx96 device (Biorad, Hercules, CA, USA).
Changes in the relative expression level were calculated
using the 2-ΔΔCt method (Biorad CFX manager software
2.1.). GAPDH was used as the endogenous control gene.Cell lysis, SDS-PAGE and Western Blotting
Cells were lysed in RIPA buffer [50 mM Tris (pH 7.5),
150 mM NaCl, 1% Triton-X-100, 0.5% sodium deoxycho-
late, 0.1% SDS, 1 mM sodium orthovanadate, 10 mM so-
dium fluoride, and 20 mM β-glycerophosphate plus
Complete protease inhibitors (Roche, Basel, Switzerland)]
and lysates were clarified by centrifugation at 16,000 × g
for 10 min. Proteins where separated by SDS-Page and
transferred to a Nitrocellulose membrane using the iBlot
Gel Transfer Device (Life Technologies). The membrane
was blocked with 0.5% blocking reagent (Roche) in PBS
containing 0.1% Tween-20 and then incubated with pri-
mary antibodies, followed by HRP- or IRDye-conjugated
secondary antibodies. Visualization was carried out using
the ECL detection system (Thermo Fischer) or the Odyssey
device (LI-COR Bioscience).
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7,5 × 104 cells/well were seeded into 96-well plates and
transfected with the miRNA library (Thermo Fischer
Scientific, see Additional file 2: Table S1) comprising
879 miRNA mimics. The RNA was transfected in a final
concentration of 10 nM using Lipofectamine RNAiMax
according to manufacturer’s instructions (Life Technolo-
gies) in two biological replicates. 72 h after transfection
the cells were either stimulated with 10 ng/ml HRG for
1 h or left untreated, followed by In-Cell Western
analysis. The miRNA library was segmented into 11 ×
96-well plates, each plate containing 80 miRNA mimics,
2 negative controls (siLacZ and miR-con) and 3 positive
controls (siErbB2, siErbB3 and miR-149-5p).
In Cell Western analysis
Cells were fixed with 4% PFA for 20 min, permeabilized
with PBS containing 0.1% Triton X-100 for 5 min and
washed twice with PBS containing 0,1% Tween 20.
Unspecific binding was blocked with 0.5% blocking
reagent (Roche) in PBS containing 0.1% Tween-20. Cells
were then incubated with primary antibodies, followed
by IRDye-conjugated secondary antibodies. Visualization
was carried out with the Odyssey device and images
were processed with the Odyssey software version 2.1.
Finally, plates were stained with crystal violet to monitor
cell density. Crystal violet was dissolved in methanol and
measured at 550 nm with the multimode reader Infinite®
200 PRO (Tecan).Screen data analysis
All statistical and bioinformatic analyses were performed
using R statistical computing environment (http://www.
R-project.org) [49]. First, raw data of each 96-well plate
was corrected for the signal decay of pAkt caused by the
successive PFA fixation of the individual columns. This
was done by comparing the medians of the first and the
last column per plate harboring the same set of controls,
which theoretically should have identical median values.
Assuming a linear signal decay, a correction value for
each column was calculated and added to the corre-
sponding column. For the corrected values, the ratio of
pAkt/Akt was calculated resulting in the value for Akt
activity. Next, the ratios were log2-transformed. HRG-
induced Akt activation was calculated by subtracting the
pAkt/Akt ratio for basal, unstimulated cells from that of
HRG-stimulated cells, yielding the increase in Akt acti-
vation upon HRG stimulation (ΔpAkt). Two-sided t-test
was applied to compare ΔpAkt of each miRNA in the
screen against negative controls and resulting p-values
were adjusted for multiple comparisons using Benjamini
& Hochberg correction [50]. miRNAs with adjusted
p-value < 0.05 were considered as significant.Viability assays
One day after transfection, 2.5 × 103 cells were plated
into 96-well plates. The next day, medium was replaced
by medium containing 0.5% FCS ± 5 ng/ml HRG. Five
days later, cells were fixed with paraformaldehyde and
stained with crystal violet. Crystal violet was dissolved in
methanol and measured at 550 nm with the multimode
reader Infinite® 200 PRO (Tecan).
Migration assays
Three days after transfection, SKBR3 cells (1 × 105) were
seeded in medium containing 0.5% FCS into Transwells
(8 μm pore size; Sigma Aldrich, St. Louis, MI, USA)
coated with 10 μg/ml collagen (Serva, Germany) on the
underside and allowed to migrate overnight. The bottom
chamber contained medium with 0.5% FCS supple-
mented with 25 ng/ml HRG. Cells on the underside of
the membranes were fixed, stained with crystal violet,
and counted in five independent microscopic fields.
Experiments were performed with duplicate filters.
Availability of supporting data
The data sets supporting the results of this article are
included within the article and its additional files.
Additional files
Additional file 1: Figure S1. In-Cell-Western establishment. MCF-7 cells
were stimulated with different HRG concentrations for different times and
analyzed by In-Cell-Western using antibodies specific for (A) Akt(pT308) and
Akt, and (B) pErk1/2 and total Erk1/2. Signals were background subtracted
and normalized to the unstimulated control. Figure S2. Distribution of
ΔpAkt values for all positive and negative controls. ΔAkt values <1 indicate
a reduction, values >2 an increase in Akt activation upon HRG stimulation.
Data analysis: one way Anova followed by Bonferroni’s multiple comparison
test (***p < 0.001, **p < 0.01). Figure S3. miRNAs and their targets (see
Figure 4). The most frequently targeted genes for miRNAs that significantly
reduced Akt activity are shown. Figure S4. Regulatory miRNA/target
network for negatively acting miRNAs. miRNAs (blue); genes (grey circles);
miRNA-target interactions (black lines); positive regulatory effects (green
lines). The network includes 19 miRNAs and 14 genes targeted by at least 9
miRNAs. Akt1 and Akt2 were included manually. Figure S5. Regulatory
miRNA/target network for positively acting miRNAs. miRNAs (blue); genes
(grey circles); miRNA-target interactions (black lines); positive regulatory
effects (green lines). The network includes 21 miRNAs and 17 genes targeted
by at least 6 miRNAs. Akt1 and Akt2 were included manually. Figure S6.
Correlation of miRNA expression with cell density. pAkt/Akt ratios and crystal
violet values were correlated for the unstimulated (basal) condition. Figure
S7. Predicted binding sites of miR-148b, miR-326 and miR-520a in the ErbB3
mRNA. Figure S8. miRNA inhibition of HRG signaling in SKBR3 cells. Cells
were transfected with the indicated miRNAs. (A) Lysates from untreated
(0 min) and HRG-stimulated cells were analyzed by immunoblotting with the
indicated antibodies Cropped panels are from the same blot. (B) Transwell
assays with HRG as a chemotactic stimulus. The mean ± SEM of two (miR-149)
or three (miR-520a-3p) independent experiments is shown.
Additional file 2: Table S1. Sequences contained in the human mimic
library. Table S2. Raw data for basal and HRG-stimulated cells. Table S3.
Lists of computationally predicted miRNA targets.
Competing interests
The authors declare that they have no competing interests.
Bischoff et al. Cell Communication and Signaling  (2015) 13:5 Page 14 of 15Authors’ contributions
AB established and performed the miRNA screen, analyzed and validated
the data. MB performed the bioinformatic analysis of the screen data. MS
performed qRT-PCR and luciferase experiments, and supported the revision
of the manuscript. SS helped with the cloning and signaling experiments.
TB supervised the screen data analysis. MAO conceived the study, analyzed
the data and wrote the manuscript with the support of AB, MS, MB and TB.
All authors read and approved the final manuscript.Acknowledgments
We thank Melanie Boerries and Hauke Busch for fruitful discussions and critically
reading the manuscript. This work was supported by DFG 571692 and DKH
110701 grants to MAO. MAO is funded by the DFG Heisenberg program.
Author details
1Institute of Cell Biology and Immunology, University of Stuttgart,
Allmandring 31, 70569 Stuttgart, Germany. 2Department of Medical Statistics,
University Medical Center Göttingen, 37099 Göttingen, Germany.
Received: 12 June 2014 Accepted: 12 January 2015
References
1. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer.
Curr Opin Cell Biol. 2009;21(2):177–84.
2. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and
discovering ERBB3. Nat Rev Cancer. 2009;9(7):463–75.
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev
Mol Cell Biol. 2001;2(2):127–37.
4. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network:
receptor heterodimerization in development and cancer. EMBO J.
2000;19(13):3159–67.
5. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, et al.
The crystal structure of a truncated ErbB2 ectodomain reveals an active
conformation, poised to interact with other ErbB receptors. Mol Cell.
2003;11(2):495–505.
6. Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious
member of the HER family, in cancer biology and cancer therapeutics.
Semin Cell Dev Biol. 2010;21(9):944–50.
7. Fayard E, Xue G, Parcellier A, Bozulic L, Hemmings BA. Protein kinase B
(PKB/Akt), a key mediator of the PI3K signaling pathway. Curr Top Microbiol
Immunol. 2010;346:31–56.
8. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5.
9. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell.
2009;136(2):215–33.
10. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N.
Widespread changes in protein synthesis induced by microRNAs. Nature.
2008;455(7209):58–63.
11. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics,
monitoring and therapeutics. A comprehensive review. EMBO Mol Med.
2012;4(3):143–59.
12. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer.
Adv Exp Med Biol. 2013;774:1–20.
13. Barker A, Giles KM, Epis MR, Zhang PM, Kalinowski F, Leedman PJ.
Regulation of ErbB receptor signalling in cancer cells by microRNA.
Curr Opin Pharmacol. 2010;10(6):655–61.
14. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ.
Regulation of epidermal growth factor receptor signaling in human cancer
cells by microRNA-7. J Biol Chem. 2009;284(9):5731–41.
15. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate
suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA
miR-125a or miR-125b. J Biol Chem. 2007;282(2):1479–86.
16. Kawano S, Ikeda W, Kishimoto M, Ogita H, Takai Y. Silencing of ErbB3/ErbB2
signaling by immunoglobulin-like Necl-2. J Biol Chem.
2009;284(35):23793–805.
17. Minami A, Shimono Y, Mizutani K, Nobutani K, Momose K, Azuma T, et al.
Reduction of the ST6 beta-galactosamide alpha-2,6-sialyltransferase 1
(ST6GAL1)-catalyzed sialylation of nectin-like molecule 2/cell adhesion
molecule 1 and enhancement of ErbB2/ErbB3 signaling by microRNA-199a.
J Biol Chem. 2013;288(17):11845–53.18. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, et al. Up-regulation of miR-21
mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem.
2011;286(21):19127–37.
19. Bischoff A, Huck B, Keller B, Strotbek M, Schmid S, Boerries M, et al. miR149
functions as a tumor suppressor by controlling breast epithelial cell
migration and invasion. Cancer Res. 2014;74(18):5256–65.
20. Croft D, O’Kelly G, Wu G, Haw R, Gillespie M, Matthews L, et al. Reactome: a
database of reactions, pathways and biological processes. Nucleic Acids Res.
2011;39(Database issue):D691–7.
21. Kramer F, Bayerlova M, Klemm F, Bleckmann A, Beissbarth T. rBiopaxParser–an R
package to parse, modify and visualize BioPAX data. Bioinformatics.
2013;29(4):520–2.
22. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for
microRNA genomics. Nucleic Acids Res. 2008;36(Database issue):D154–8.
23. Wang X. miRDB: a microRNA target prediction and functional annotation
database with a wiki interface. RNA. 2008;14(6):1012–7.
24. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource:
targets and expression. Nucleic Acids Res. 2008;36(Database issue):D149–53.
25. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al.
STRING v9.1: protein-protein interaction networks, with increased coverage
and integration. Nucleic Acids Res. 2013;41(Database issue):D808–15.
26. Niepel M, Hafner M, Pace EA, Chung M, Chai DH, Zhou L, et al. Analysis of
growth factor signaling in genetically diverse breast cancer lines. BMC Biol.
2014;12:20.
27. Breuleux M. Role of heregulin in human cancer. Cell Mol Life Sci.
2007;64(18):2358–77.
28. Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C, Lupu R. Heregulin is
sufficient for the promotion of tumorigenicity and metastasis of breast
cancer cells in vivo. Mol Cancer Res. 2003;1(3):165–75.
29. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A
central role for HER3 in HER2-amplified breast cancer: implications for
targeted therapy. Cancer Res. 2008;68(14):5878–87.
30. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas 3rd CF, Hynes NE. The
ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires
ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A.
2003;100(15):8933–8.
31. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape
from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive
HER3. Nature. 2007;445(7126):437–41.
32. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, et al. Targeting ADAM-
mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small
cell lung cancer. Cancer Cell. 2006;10(1):39–50.
33. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, et al. Involvement of miR-326
in chemotherapy resistance of breast cancer through modulating
expression of multidrug resistance-associated protein 1. Biochem Pharmacol.
2010;79(6):817–24.
34. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, et al. microRNA-205
regulates HER3 in human breast cancer. Cancer Res. 2009;69(6):2195–200.
35. Uhlmann S, Mannsperger H, Zhang JD, Horvat EA, Schmidt C, Kublbeck M,
et al. Global microRNA level regulation of EGFR-driven cell-cycle protein net-
work in breast cancer. Mol Syst Biol. 2012;8:570.
36. Duffy MJ, McKiernan E, O’Donovan N, McGowan PM. Role of ADAMs in
cancer formation and progression. Clin Cancer Res. 2009;15(4):1140–4.
37. Cimino D, De Pitta C, Orso F, Zampini M, Casara S, Penna E, et al. miR148b
is a major coordinator of breast cancer progression in a relapse-associated
microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1.
FASEB J. 2013;27(3):1223–35.
38. Song YX, Yue ZY, Wang ZN, Xu YY, Luo Y, Xu HM, et al. MicroRNA-148b is
frequently down-regulated in gastric cancer and acts as a tumor suppressor
by inhibiting cell proliferation. Mol Cancer. 2011;10:1.
39. Leivonen SK, Sahlberg KK, Makela R, Due EU, Kallioniemi O, Borresen-Dale
AL, et al. High-throughput screens identify microRNAs essential for HER2
positive breast cancer cell growth. Mol Oncol. 2014;8(1):93–104.
40. Frische EW, Zwartkruis FJ. Rap1, a mercenary among the Ras-like GTPases.
Dev Biol. 2010;340(1):1–9.
41. Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A,
et al. MicroRNA-520/373 family functions as a tumor suppressor in estrogen
receptor negative breast cancer by targeting NF-kappaB and TGF-beta
signaling pathways. Oncogene. 2012;31(37):4150–63.
42. Xu M, Mo YY. The Akt-associated microRNAs. Cell Mol Life Sci.
2012;69(21):3601–12.
Bischoff et al. Cell Communication and Signaling  (2015) 13:5 Page 15 of 1543. Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in
breast cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(8):1236–43.
44. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, et al. The
microRNAs miR-373 and miR-520c promote tumour invasion and metastasis.
Nat Cell Biol. 2008;10(2):202–10.
45. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges
and limitations. Nat Rev Cancer. 2009;9(8):550–62.
46. Dyer BW, Ferrer FA, Klinedinst DK, Rodriguez R. A noncommercial dual
luciferase enzyme assay system for reporter gene analysis. Anal Biochem.
2000;282(1):158–61.
47. Koressaar T, Remm M. Enhancements and modifications of primer design
program Primer3. Bioinformatics. 2007;23(10):1289–91.
48. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al.
Primer3–new capabilities and interfaces. Nucleic Acids Res. 2012;40(15):e115.
49. Team RC. R: A language and environment for statistical computing. Vienna,
Austria: R Foundation for Statistical Computing; 2012. 3-900051-07-0.
50. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical
and powerful approach to multiple testing. J Roy Stat Soc B Met. 1995;57
(1):289–300.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
